in the field of life and health-凯发k8国际首页登录

mother herb

after more than 10 years of painstaking research, it has been found that the monomer extracted and chemically synthesized from chinese herbal motherwort, mother-motherline (also known as scm-198), has obvious efficacy on hyperlipidemia, atherosclerosis and stroke and other diseases. mother herb has been confirmed to have a significant lipid-lowering effect, which can inhibit the inflammation of atherosclerotic plaques and reduce the area of cerebral cortex infarction caused by cerebral ischemia, which has a fast and significant effect on the treatment of acute stroke, bringing good news to middle-aged and elderly patients with cardiovascular and cerebrovascular diseases. 

at present, the project has applied for patent protection, has obtained the "drug clinical trial approval" issued by the state drug administration, and its phase i, ii. and iii clinical trials have been approved at one time, and have now entered the clinical phase ii trial, and at the same time approved clinical research in the united states through the us fda. 

intention to cooperate in:

it can be technology transfer, cooperative development, joint venture production, etc.

prospective partner category :

cooperation between scientific research institutions and enterprises is the mainstay, but it is not limited to this.

yew sirna new drug technology

small interfering nucleic acid sirna drugs are one of the fastest growing new biomedicines today, and new drug candidates can be quickly designed according to the target gene mrna, but sirna drugs cannot be designed for diseases with unknown targets. to this end, the team of professor jiang zhihong, director of the state key laboratory of quality research in traditional chinese medicines of macau university of science and technology, adopted a research strategy that is contrary to the current sirna drug design, and through the established rna omics platform, the rna molecule trf-t11 with strong cytotoxicity to tumor cells was screened from the southern yew tree, and the proliferation of ovarian cancer was inhibited by the rnai mechanism. the research was published as a cover article (2022, 27, 718-732) in the world-renowned cell press journal molecular therapy-nucleic acids (top 10% in the field of medicine-research and experimentation, impact factor 8.886). this is the world's first original discovery on plant trna and its fragments to treat diseases by regulating genes, fully demonstrating m.u.s.'s comprehensive strength in the field of medicinal plant rna research. the research results have been authorized by chinese, australian and american patents, and in 2020, the "technology transfer contract" was signed with yingkerui (hong kong) innovative pharmaceutical co., ltd., which realized the transformation of scientific research achievements of universities. at present, the project is in the preclinical research and development stage, including active sequence optimization, new dosage form research and activity evaluation. in the future, the two sides will jointly promote the development of the world's first new sirna drug of plant origin.

figure 1. the rna omics platform facilitates the discovery of yew sirna molecules

figure 2. yew sirna significantly inhibits ovarian cancer proliferation

figure 3. high-resolution mass spectrometry for yew sirna analysis

figure 4. yew sirna research team group photo

ginseng rna-a, ginseng rna-b, probiotic rna new drug technology

the three new drug technologies of "ginseng rna-a", "ginseng rna-b" and "probiotic rna" and related 9 patent rights led by the research team of professor jiang zhihong, vice president of macau university of science and technology and director of the state key laboratory of quality research in chinese medicines, signed the "technology transfer contract" with macau tak shing biotechnology co., ltd. these indicate the success of a group of potential rna sequences independently bred in macao in the transformation of scientific and technological achievements.

kr2 eye drops

this product is a class 1 innovative drug, the indications are mainly used for the treatment of wet macular degeneration, diabetic retinopathy, iris neovascularization and corneal neovascularization and other blinding eye diseases.

professor zhang kang obtained a new structure of active small molecule compound kr2 through a large number of studies, the mechanism of action is to inhibit vegfr2 activity to inhibit the formation of new blood vessels in the eye, and successfully developed it as an eye drop, through eye drops administration to achieve non-invasive treatment. according to the preclinical research evaluation of the drug and human clinical trials, the drug has a high safety and obvious therapeutic effect, which can greatly reduce the treatment cost of patients and alleviate the pain of treatment of patients. at present, the drug has 2 international pct patents and has been authorized by 8 national patents

this product is a class 1 innovative drug, the indications are mainly used for the treatment of wet macular degeneration, diabetic retinopathy, iris neovascularization and corneal neovascularization and other blinding eye diseases.

professor zhang kang obtained a new structure of active small molecule compound kr2 through a large number of studies, the mechanism of action is to inhibit vegfr2 activity to inhibit the formation of new blood vessels in the eye, and successfully developed it as an eye drop, through eye drops administration to achieve non-invasive treatment. according to the preclinical research evaluation of the drug and human clinical trials, the drug has a high safety and obvious therapeutic effect, which can greatly reduce the treatment cost of patients and alleviate the pain of treatment of patients. at present, the drug has 2 international pct patents and has been authorized by 8 national patents.

intention to cooperate in:

it can be technology transfer, cooperative development, joint venture production, etc.

prospective partner category :

cooperation between scientific research institutions and enterprises is the mainstay, but it is not limited to this.

红外治疗

利用红外（振频）治疗是大学 “埃尔文内尔博士生物物理与创新药物实验室” 主任黄锦伟教授科研团队，与新元科技（亚洲）有限公司携手，于2017年联合创立 “eefit 传导型远红外技术生物医学项目”，借助eefit依飞的微观物理技术和产品，进行 “红外（振频）治疗” 专案研究，用于开创物理科技与基因调控创新疗法。

所利用的eefit依飞产品包括: “依飞神笔”及“活络仪2”；

两项专利设计产品均是以微观物理能量技术，结合生物医学机制及中医经络学理论而成的创新科技，功效显著，轻巧便携，适合大众日常使用。“eefit 传导型微观物理技术产品”，让大众体验、并实现以先进科技改善身体健康。

（1））"依飞神笔"可以用于舒缓各种痛症及美容养生，外观设计时尚、轻巧，使用方便，功效强大；其释出的能量会被皮肤和经络穴位迅速吸收，并产生共振效应，有效改善血液微循环。

 图1：依飞神笔

（2）"活络仪2"是继"依飞神笔"后的另一创新核心推介，设计和操作上更灵巧方便，磁贴片设计可以让产品因需要固定于衣物上，方便照射患处，让身体长时间吸收能量，达到随时随地无痛通淋巴、迅速去水肿、排走毒素、舒缓不适、强身健体、养生美容等多重功效。

 图2：活络仪2

图3：作用原理图

自然宁草本膏

自然宁草本膏是由中药品质研究国家重点实验室（澳门科技大学）的研究人员多年潜心研制“中药鲜品”的创新转化成果。通过与本澳企业药谷中药有限公司的深入合作，立足推动澳门本地研发制造，助力打造出安全有效的现代中药皮肤制剂。 该项目在2018年获得澳门科学技术发展基金首批企业创新研发资助计划（023/2017/air）的支援，得以成功完成本澳产品中试制。产品主要活性成分来自药食同源的中药鲜“紫苏叶”，经过现代提取技术、加工工艺制成，成份天然、安全，质量可控，广泛适用于湿疹、青春痘、红肿痕痒等。 紫苏叶性辛味温，具有解表散寒，行气和胃的功效。据《普济方》记载其研细外用可治恶疮、疥廯，但其活性成分的有效提取凝聚了科研人员反复的工艺优化和活性筛选过程。最后研究人员有幸从鲜紫苏叶中获取到有效成分制备成的水凝胶，性质温和，气味芬芳，尤其对批复湿疹且长期使用激素类药物依赖性皮炎具有显著功效。产品适宜人群广泛，接受度高。